Sysmex Inostics is a leader in blood-based cell-free tumor DNA oncology testing services. The company’s OncoBEAM™ assays detect clinically actionable gene mutations in cancer allowing for more targeted therapies and monitoring of disease response and recurrence. Sysmex Inostics has a CLIA-certified laboratory in Baltimore, Maryland and a GCP laboratory in Hamburg, Germany. The company also offers global comprehensive services for Pharmaceutical and CRO companies — from discovery to companion diagnostics.
Benitec Biopharma Limited is a public biotechnology company (ASX:BLT; OTC: BTEBY) developing its transformational gene silencing technology, ddRNAi, for a range of chronic and life-threatening diseases. These include hepatitis C and B, drug-resistant lung cancer and age-related macular degeneration. Benitec has also licensed ddRNAi for HIV/AIDS, intractable pain, Huntington’s disease and retinitis pigmentosa
UbiVac is a clinical stage biotechnology company with three platform immunotherapy technologies for cancer and infectious disease. UbiVac’s lead product, DPV-001, a first-in-class DC-targeted complex vaccine/combination immunotherapy is being tested in prostate cancer and in an NCI-funded randomized multi-center phase II trial for NSCLC. Trials for breast cancer, HNSCC and mesothelioma will open in 2015. Nanoparticle and disabled-CMV vaccines are in preclinical testing.
XBiotech is a leading developer of biological therapies—including a pipeline of True Human™ antibodies and proven blockbuster biosimilars. To support these programs, XBiotech has developed the manufacturing technology to enable production of biological drugs with an unprecedented low cost of goods.
Interested in Sponsorship?
If you would like to download our sponsorship brochure please enter your email below: